Identification and Initial Optimization of Inhibitors of Clostridium Difficile (C. Difficile) Toxin B (TcdB)
Overview
Authors
Affiliations
The discovery, synthesis and preliminary structure-activity relationship (SAR) of a novel class of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB) is described. A high throughput screening (HTS) campaign resulted in the identification of moderately active screening hits 1-5 the most potent of which was compound 1 (IC = 0.77 µM). In silico docking of an early analog offered suggestions for structural modification which resulted in the design and synthesis of highly potent analogs 13j(IC = 1 nM) and 13 l(IC = 7 nM) which were chosen as leads for further optimization.
Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.
Sakari M, Laisi A, Pulliainen A ACS Infect Dis. 2022; 8(3):433-456.
PMID: 35099182 PMC: 8922280. DOI: 10.1021/acsinfecdis.1c00296.
Yakovlieva L, Fulleborn J, Walvoort M Front Microbiol. 2021; 12:745702.
PMID: 34630370 PMC: 8498110. DOI: 10.3389/fmicb.2021.745702.
Recent advances in the treatment of using biotherapeutic agents.
Giau V, Lee H, An S, Hulme J Infect Drug Resist. 2019; 12:1597-1615.
PMID: 31354309 PMC: 6579870. DOI: 10.2147/IDR.S207572.
Stroke I, Letourneau J, Miller T, Xu Y, Pechik I, Savoly D Antimicrob Agents Chemother. 2018; 62(5).
PMID: 29483125 PMC: 5923158. DOI: 10.1128/AAC.00107-18.